Allogeneic Expanded Gamma Delta T Cells With GD2 Chemoimmunotherapy in Relapsed /Refractory Neuroblastoma or Refractory/ Relapsed Osteosarcoma

NCT05400603 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

24

Enrollment

OTHER

Sponsor class

Conditions

Neuroblastoma
Refractory Neuroblastoma
Relapsed Neuroblastoma
Relapsed Osteosarcoma
Refractory Osteosarcoma

Interventions

COMBINATION_PRODUCT: Ex Vivo Expanded Allogeneic γδ T Cells in Combination with Dinutuximab, Temozolomide, Irinotecan and Zoledronate

Sponsor

Emory University